alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM
THE UNAUDITED FINANCIAL STATEMENTS OF PHYSICIAN CORPORATION OF
AMERICA FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 1997 AND IS
QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          DEC-31-1996
<PERIOD-START>                             JAN-01-1997
<PERIOD-END>                               JUN-30-1997
<CASH>                                          88,472
<SECURITIES>                                   138,009
<RECEIVABLES>                                   65,567
<ALLOWANCES>                                    53,799
<INVENTORY>                                        595
<CURRENT-ASSETS>                               443,948
<PP&E>                                          49,818
<DEPRECIATION>                                (26,487)
<TOTAL-ASSETS>                               1,130,045
<CURRENT-LIABILITIES>                          551,226
<BONDS>                                          9,489
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                           388
<OTHER-SE>                                    (56,287)
<TOTAL-LIABILITY-AND-EQUITY>                 1,130,045
<SALES>                                        721,997
<TOTAL-REVENUES>                               742,612
<CGS>                                          711,788
<TOTAL-COSTS>                                  720,788
<OTHER-EXPENSES>                                    50
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                               9,215
<INCOME-PRETAX>                                 12,559
<INCOME-TAX>                                   (1,450)
<INCOME-CONTINUING>                             11,109
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                    11,109
<EPS-PRIMARY>                                     0.17
<EPS-DILUTED>                                     0.17
        

</TABLE>
§ 209.10 Content and format of the side effects statement. ( a ) *Content.* The side effects statement provided with each prescription drug product approved under section 505 of the act must read: “Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.”
( b ) *Format.* The side effects statement must be in a single, clear, easy-to-read type style. The letter height or type size used for the side effects statement in accordance with paragraphs (b)(1) and (b)(2) of § 209.11 must be no smaller than 6 points (1 point = 0.0138 inch). The letter height or type size for the side effects statement under paragraphs (b)(3), (b)(4), and (b)(5) of § 209.11 must be no smaller than 10 points.
---

EXHIBIT 32.2

CERTIFICATION

I, James Vandeberg, Chief Financial Officer of IAS Communications, Inc. certify
  that:

|1. | I have reviewed this annual report on Form 10-KSB of IAS
      Communications, Inc.;                                                                                                                                                                                                                                                                        
|-- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|   |                                                                                                                                                                                                                                                                                                                                                             
|2. | Based on my knowledge, this annual report
        does not contain any untrue statement of a material fact or omit to state
        a material fact necessary to make the statements made, in light of the
        circumstances under which such statements were made, not misleading with
        respect to the period covered by this annual report; and
|   |                                                                                                                                                                                                                                                                                                                                                             
|3. | Based on my knowledge, the financial
        statements, and other financial information included in this annual report,
        fairly present in all material respects the financial condition, results
        of operations and cash flows of the registrant as of, and for, the periods
        presented in this annual report.                       

| | IAS TECHNOLOGIES, INC.
| | ----------------------
| |                       
| | By:                   
| |                       
| |                       
| |                       

Date: September 18, 2003

---
<PAGE>   1
                                                                   EXHIBIT 23.01


                       CONSENT OF INDEPENDENT ACCOUNTANTS



We hereby consent to the incorporation by reference in the Registration
Statements on Form S-8 (No. 33-92902, No. 333-14323 and No. 333-18871) of HNC
Software Inc. of our report dated January 21, 1997 appearing on page 37 of the
Annual Report to Stockholders which is incorporated in this Annual Report on
Form 10-K/A-Amendment No. 1.  We also consent to the incorporation by reference
in the Prospectus constituting part of the Registration Statement on Form S-3
(No. 333-22735) of HNC Software Inc. of our report dated January 21, 1997
appearing on page 37 of the Annual Report to Stockholders which is incorporated
in this Annual Report on Form 10-K/A Amendment No. 1.





PRICE WATERHOUSE LLP

San Diego, California
April 10, 1997
EX-10.1






CERTAIN COMPENSATION AND BENEFIT

ARRANGEMENTS WITH

HEALTH NET, INC.’S

NON-EMPLOYEE DIRECTORS

AS AMENDED AND RESTATED ON JULY 27, 2006




Upon recommendation of the Governance Committee of the Board of Directors of Health Net, Inc.
(the “Company”), the Board of Directors of the Company (the “Board”) has approved the following
compensation and benefit arrangements with each non-employee director of the Board in respect of
his/her service on the Board:




	 	•	 	an annual retainer of $45,000 per year for each non-employee director;






	 	•	 	an annual retainer of $10,000 per year for the Chair of each of the Compensation
Committee, Governance Committee and Finance Committee;






	 	•	 	an annual retainer of $15,000 for the Chair of the Audit Committee;






	 	•	 	meeting fee of $2,000 for each meeting of the Board of Directors attended, and a
$1,000 fee for each committee meeting attended, other than the Audit Committee, which
meeting fee is $2,000 for each audit committee meeting attended;






	 	•	 	in lieu of the above listed retainer and meeting fees, the Chairman of the Board
receives $16,667 per month for his services;






	 	•	 	reimbursement of customary expenses for attending Board, committee and shareholder
meetings; and






	 	•	 	optional medical, dental and vision coverage for non-employee directors and their
eligible dependents, which directors can continue to utilize following their retirement
from the Board. Non-employee directors will pay monthly premiums for any such coverage
they elect at the same rates paid by Company employees without taking into account the
Company’s subsidization of employees’ monthly premiums.





In addition, the non-employee directors of the Company are eligible to participate in the
Company’s 2006 Long-Term Incentive Plan (the “Plan”). Under the Plan, shares of Common Stock are
reserved for initial grants of nonqualified stock options to directors when they join the Company’s
Board and automatic annual grants of nonqualified stock options on each year such director is
re-elected to the Company’s Board. Each non-employee director grant entitles the optionee to
purchase the granted number of shares of Common Stock (which number is determined pursuant to grant
formula provisions approved by the Board of Directors) at an exercise price equal to the fair
market value of Common Stock on the date of such grant. Each grant vests as to 33 1/3% of the
shares each year on the anniversary of the date of the grant, provided that the options become
immediately exercisable in the event of a “change in control” of the Company, as defined in the
Plan.



Furthermore, the Company maintains a deferred compensation plan pursuant to which non-employee
directors are eligible to defer up to 100% of their compensation. The compensation deferred under
such plan is credited with earnings or losses measured by the rate of return on investments elected
by plan participants. Each plan participant is fully vested in all deferred compensation and
earnings credited to his or her account.
I 

118TH CONGRESS 

2D SESSION H. R. 7347 

To amend title 38, United States Code, to direct the Secretary of Veterans 

Affairs to report on whether the Secretary will include certain psychedelic 

drugs in the formulary of the Department of Veterans Affairs. 

IN THE HOUSE OF REPRESENTATIVES 

FEBRUARY 14, 2024 

Mr. VAN ORDEN introduced the following bill; which was referred to the 

Committee on Veterans’ Affairs 

A BILL 

To amend title 38, United States Code, to direct the Secretary of Veterans Affairs to report on whether the Secretary will include certain psychedelic drugs in the formulary of the Department of Veterans Affairs. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 


ssavage on LAPJG3WLY3PROD with BILLS
2 

•HR 7347 IH

1 SECTION 1. REPORTING OF DETERMINATION OF THE SEC2 RETARY OF VETERANS AFFAIRS WHETHER 

3 TO INCLUDE NEWLY APPROVED OR LI4 CENSED PSYCHEDELIC DRUGS IN THE FOR5 MULARY OF THE DEPARTMENT OF VETERANS 

6 AFFAIRS. 

7 Chapter 81 of title 38, United States Code, is amend8 ed by inserting, after section 8125, the following new sec9 tion (and conforming the table of sections at the beginning 

10 of such chapter accordingly): 

11 ‘‘§ 8125A. Reporting of determination whether to in12 clude newly approved or licensed psyche13 delic drugs in the formulary of the De14 partment 

15 ‘‘Not later than 180 days after a psychedelic drug 

16 is approved under section 505 of the Federal Food, Drug, 

17 and Cosmetic Act (21 U.S.C. 355) or licensed under sec18 tion 351 of the Public Health Service Act (42 U.S.C. 262), 

19 the Secretary shall submit to the Committees on Veterans’ 

20 Affairs of the Senate and House of Representatives a re21 port regarding such drug, that includes— 

22 ‘‘(1) the determination of the Secretary whether 

23 to include such drug in the formulary of the Depart24 ment; and 


ssavage on LAPJG3WLY3PROD with BILLS
3 

•HR 7347 IH

1 ‘‘(2) the justification of the Secretary for such 

2 determination.’’. 

Æ 


ssavage on LAPJG3WLY3PROD with BILLS
nbr_EX10_2


		
			Exhibit 10.2
		

		
			 
		

		
			STOCK OPTION AGREEMENT
		

		
			NABORS INDUSTRIES LTD.
		

		
			 
		

		
			This Stock Option Agreement, effective as of ____________ between NABORS INDUSTRIES LTD. (“Company”) and ___________ (“Optionee”),
		

		
			 
		

		
			WHEREAS, Optionee is now a Non-Employee Director of the Company, and
		

		
			 
		

		
			WHEREAS, the purpose of the Nabors Industries Ltd. 1999 Stock Option Plan for Non-Employee Directors (the “Plan”) is to promote the interests of the Company and its shareholders by strengthening the Company’s ability to attract and retain the services of experienced and knowledgeable directors and by encouraging such directors to acquire increased proprietary interest in the Company and
		

		
			 
		

		
			WHEREAS, the achievement of these goals will be assisted by the grant of an option to purchase shares of the Company’s Common Shares, $.001 par value (the “Stock”),
		

		
			 
		

		
			NOW THEREFORE, the parties mutually agree as follows:
		

		
			 
		

		
			1.         Grant of Option.  Effective _______________, the Company grants to Optionee the option to purchase ________ shares of Stock (“Optioned Stock”), subject to the terms and conditions set forth herein and in the Plan.  A copy of the Plan is attached hereto and is made part of the 1999 Stock Option Agreement for Non-Employee Directors.
		

		
			 
		

		
			2.         Option Price.  The price at which each share of Optioned Stock may be purchased shall be $______ per share of Optioned Stock.
		

		
			 
		

		
			3.         Vesting of Options.  The options shall vest immediately.
		

		
			 
		

		
			4.         Optionee Acknowledgment.  The Optionee agrees to be bound by the terms of the Option Agreement and the Plan.
		

		
			 
		

		
			IN WITNESS WHEREOF, the Optionee has duly executed this Agreement as of the day and year first written above.
		

		
			 
		

			
					
						 

					
					
						Optionee

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						By:

					
					
						 

				
	
					
						 

					
					
						 

					
					
						Optionee

				



		
			 
		

		
			
		

		
			


		 


 



		

		
			IN WITNESS WHEREOF, the Company has caused this Option Agreement to be duly executed by its duly authorized officer as of the day and year first above written.
		

		
			 
		

			
					
						COMPANY:

					
					
						NABORS INDUSTRIES LTD.

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						By:
§ 1309.44 Suspension of registration pending final order. ( a ) The Administrator may suspend any registration simultaneously with or at any time subsequent to the service upon the registrant of an order to show cause why such registration should not be revoked or suspended, in any case where he finds that there is an imminent danger to the public health or safety. If the Administrator so suspends, he shall serve with the order to show cause pursuant to § 1309.46 an order of immediate suspension that shall contain a statement of his findings regarding the danger to public health or safety.
( b ) Upon service of the order of immediate suspension, the registrant shall promptly return his Certificate of Registration to the nearest office of the Administration. Also, upon service of the order of immediate suspension, the registrant shall, as instructed by the Administrator: ( 1 ) Deliver to the nearest office of the Administration or to authorized agents of the Administration all of the particular chemical or chemicals in his or her possession that were obtained under the authority of a registration or an exemption from registration granted by the Administrator by regulation, which are affected by the revocation or suspension; or
( 2 ) Place all of such chemicals under seal as described in section 304(f) of the Act (21 U.S.C. 824(f)).
( c ) Any suspension shall continue in effect until the conclusion of all proceedings upon the revocation or suspension, including any judicial review thereof, unless sooner withdrawn by the Administrator or dissolved by a court of competent jurisdiction. Any registrant whose registration is suspended under this section may request a hearing on the revocation or suspension of his registration at a time earlier than specified in the order to show cause pursuant to Section 1309.46, which request shall be granted by the Administrator, who shall fix a date for such hearing as early as reasonably possible.
[60 FR 32454, June 22, 1995, as amended at 62 FR 5916, Feb. 10, 1997]
II 

Calendar No. 539 

118TH CONGRESS 

2D SESSION H. R. 7180 

IN THE SENATE OF THE UNITED STATES 

JUNE 4, 2024 

Received; read twice and referred to the Committee on Homeland Security and 

Governmental Affairs 

SEPTEMBER 25, 2024 

Reported by Mr. PETERS, without amendment 

AN ACT 

To designate the facility of the United States Postal Service 

located at 80 1st Street in Kingsland, Arkansas, as 

the ‘‘Kingsland ‘Johnny Cash’ Post Office’’. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. KINGSLAND ‘‘JOHNNY CASH’’ POST OFFICE. 

4 (a) DESIGNATION.—The facility of the United States 

5 Postal Service located at 80 1st Street in Kingsland, Ar6 kansas, shall be known and designated as the ‘‘Kingsland 

7 ‘Johnny Cash’ Post Office’’. 


ssavage on LAPJG3WLY3PROD with BILLS
2 

•HR 7180 RS

1 (b) REFERENCES.—Any reference in a law, map, reg2 ulation, document, paper, or other record of the United 

3 States to the facility referred to in subsection (a) shall 

4 be deemed to be a reference to the ‘‘Kingsland ‘Johnny 

5 Cash’ Post Office’’. 


ssavage on LAPJG3WLY3PROD with BILLS

ssavage on LAPJG3WLY3PROD with BILLS
Calendar No. 539 

118TH CONGRESS 

2D SESSION H. R. 7180 

AN ACT 

To designate the facility of the United States PostOffice’’. Arkansas, as the ‘‘Kingsland ‘Johnny Cash’ Post al Service located at 80 1st Street in Kingsland, 

SEPTEMBER 25, 2024 

Reported without amendment 


ssavage on LAPJG3WLY3PROD with BILLS
<PAGE>
 
                                                                    Exhibit 21.0

 

                          EVEREN CAPITAL CORPORATION
                                 SUBSIDIARIES

<TABLE> 
<CAPTION> 
                                                                           STATE OF
                                                                           --------
NAME                                                                    INCORPORATION
----                                                                    -------------
<S>                                                                     <C> 
EVEREN Thrift Holdings, Inc. ..................................................Delaware
EVEREN Securities Holdings, Inc. ..............................................Delaware
     Bateman Eichler, Hill Richards Realty Services, Inc. ...................California
          Bateman Eichler, Hill Richards Housing Investors, Inc. ............California
     Bateman Eichler, Hill Richards Realty Co., Incorporated ................California
     BPL Holdings, Inc. .......................................................Delaware
          Boettcher FTZ Building, Inc. ........................................Colorado
          BPL Corporation. ....................................................Delaware
          Seven Sisters Corp. .................................................Delaware
     EVEREN Mortgage Group, Inc. ..............................................Delaware
          Gateway Mortgage Acceptance Corporation..............................Delaware
     EVEREN Securities, Inc. ..................................................Delaware
     ESI Fund Management, Inc. ................................................Delaware
     ESI Insurance Agency, Inc. of Colorado....................................Colorado
     ESI Insurance Agency, Inc. of Hawaii........................................Hawaii
     ESI Insurance Agency, Inc. of Nevada........................................Nevada
     ESI Insurance Agency, Inc. of Utah............................................Utah
     ESI Insurance Agency, Inc. of Wyoming......................................Wyoming
     ESI (MA) Insurance Agency. Inc. .....................................Massachusetts
     Prescott Realty Services, Inc. ...............................................Ohio
     Bateman Eichler, Hill Richards, Inc. (dormant)............................Delaware
     Boettcher & Company, Inc. (dormant).......................................Delaware
     Blunt, Ellis & Loewi, Inc. (dormant)......................................Delaware
     Lovett Underwood Neuhaus & Webb, Inc. (dormant)...........................Delaware
     Prescott, Ball & Turben, Inc. (dormant)...................................Delaware
</TABLE>
§ 139.120 Milk macaroni products. ( a ) Milk macaroni products are the class of food, each of which conforms to the definition and standard of identity and is subject to the requirements for label statement of ingredients prescribed for macaroni products by § 139.110(a), (f)(2), (f)(3), and (g), except that: ( 1 ) Milk is used as the sole moistening ingredient in preparing the dough; or in lieu of milk one or more of the milk ingredients specified in paragraph (f) of this section is used, with or without water, in such quantity that the weight of milk solids therein is not less than 3.8 percent of the weight of the finished milk macaroni product; and
( 2 ) None of the optional ingredients permitted by § 139.110(a) (1) and (2) is used. When the optional ingredient gum gluten (§ 139.110(a)(5)) is added, the quantity is such that the protein derived therefrom, together with the protein derived from semolina, durum flour, farina, flour, or any combination of these used, does not exceed 13 percent of the weight of the finished food.
( b ) Milk macaroni is the milk macaroni product the units of which conform to the specifications of shape and size prescribed for macaroni by § 139.110(b).
( c ) Milk spaghetti is the milk macaroni product the units of which conform to the specifications of shape and size prescribed for spaghetti by § 139.110(c).
( d ) Milk vermicelli is the milk macaroni product the units of which conform to the specifications of shape and size prescribed for vermicelli by § 139.110(d).
( e ) The name of each food for which a definition and standard of identity is prescribed by this section is “Milk Macaroni Product”; or alternatively, the name is “Milk macaroni”, “Milk spaghetti”, or “Milk vermicelli”, as the case may be, when the units of the food comply with the requirements of paragraph (b), (c), or (d), respectively, of this section.
( f ) The milk ingredients referred to in paragraph (a)(1) of this section are concentrated milk, evaporated milk, dried milk, and a mixture of butter with skim milk, concentrated skim milk, evaporated skim milk, nonfat dry milk (dried skim milk), or any two or more of these, in such proportion that the weight of nonfat milk solids in such mixture is not more than 2.275 times the weight of milk fat therein.
[42 FR 14409, Mar. 15, 1977, as amended at 58 FR 2878, Jan. 6, 1993]